Guilin Sanjin Of China Seeks To Be First To Try IPO In Nine Months
This article was originally published in PharmAsia News
Executive SummaryChina's Guilin Sanjin Pharmaceutical is busy promoting itself to potential institutional investors as it attempts to be the nation's first company to go public in nine months. Guilin Sanjin is launching an initial public offering, now free to do so after regulators lifted a freeze on IPOs as of June 18. The medium-size drug maker seeks to raise nearly $93 million by going public. (Click here for more
You may also be interested in...
Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.